加兰他敏:回顾它的使用在阿尔茨海默氏症。

文章的细节

引用

复制到剪贴板

果阿斯科特•LJ KL

加兰他敏:回顾它的使用在阿尔茨海默氏症。

药。2000年11月,60 (5):1095 - 122。

PubMed ID

11129124 (在PubMed

]

文摘

目前,乙酰胆碱酯酶抑制剂(疼痛)是最有前途的一类药物用于治疗阿尔茨海默病(AD)。加兰他敏是一个可逆的,竞争力,高等生物碱疼痛抑制剂。疼痛的药物是有选择性的而不是butyrylcholinesterase。除了抑制疼痛加兰他敏变构与烟碱乙酰胆碱受体相互作用加强在这些受体受体激动剂的作用。接受加兰他敏16或24毫克/天取得了显著改善认知和全球症状相对于安慰剂组在大型(n = 285 - 978患者轻度至中度AD)精心设计的试验,3到6个月的时间。加兰他敏也改善了这些患者的日常生活活动,显著降低护理援助活动的日常生活要求。此外,加兰他敏接受者取得更好的结果比安慰剂组的行为症状。在长期研究中(12个月),加兰他敏24毫克/天减缓疾病的症状的发展和维护患者的认知功能和日常生活活动轻度至中度的广告。加兰他敏是一般耐受性良好,不良事件的大部分被轻度至中度强度和瞬态。可以预见的是,不良事件在性质和胆碱能通常与胃肠道系统有关。 These effects were reduced in patients receiving the recommended dose escalation regimen. Galantamine had no clinically relevant effects on vital signs, haematological or biochemical laboratory parameters and, importantly, there were no reports of hepatotoxicity. The incidence of serious adverse events was similar between galantamine (8 to 32 mg/day) and placebo groups (6 to 16% of patients across all treatment groups). CONCLUSIONS: Galantamine is an effective well tolerated symptomatic treatment for AD which improves cognition, function and activities of daily living in the short term (up to 6 months) in patients with mild to moderate AD. In addition, it delays the development of behavioural disturbances and psychiatric symptoms, and reduces caregiver burden (as measured by caregiver time). In the long term (up to 1 year), galantamine maintains cognition and activities of daily living. Adverse events associated with galantamine are mainly cholinergic, usually mild to moderate in intensity and transient. Galantamine has been evaluated in several large well-designed studies and, given the relative lack of established treatment options, it may be considered as one of the first-line pharmacological treatments in patients with mild to moderate AD.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

加兰他敏